Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zolbetuximab + mFOLFOX6
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Zolbetuximab + mFOLFOX6 is a **combination therapy** consisting of **zolbetuximab**, a monoclonal antibody targeting claudin 18.2, and the **mFOLFOX6 chemotherapy regimen**, which includes oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil. Zolbetuximab acts by binding to claudin 18.2 on tumor cells and inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to cancer cell death. mFOLFOX6 is an established antineoplastic regimen; oxaliplatin forms DNA adducts causing cytotoxicity, 5-fluorouracil inhibits thymidylate synthase disrupting DNA synthesis, and leucovorin enhances the binding of 5-fluorouracil to thymidylate synthase. This combination is being investigated particularly for advanced and metastatic gastrointestinal cancers, such as gastric or gastroesophageal junction adenocarcinoma.
- Brand names
- Vyloy
- Other names
- zolbetuximab + oxaliplatin + leucovorin + fluorouracilzolbetuximab + mFOLFOX6
02
Targets
Claudin 18.2DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on zolbetuximab + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zolbetuximab + mFOLFOX6.